$3.23
19.05%
Nasdaq, Fri, Sep 27 2024
ISIN
US1920031010
Symbol
DNAY

Codex DNA Inc Stock price

$3.23
-0.20 5.83% 1M
-4.87 60.12% 6M
-3.95 55.03% YTD
-16.21 83.38% 1Y
-193.15 98.36% 3Y
-329.77 99.03% 5Y
-329.77 99.03% 10Y
Nasdaq, Closing price Fri, Sep 27 2024
-0.76 19.05%
ISIN
US1920031010
Symbol
DNAY
Sector
Industry

Key metrics

Market capitalization $7.07m
Enterprise Value $62.79m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.58
P/S ratio (TTM) P/S ratio 0.40
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -43.65%
Revenue (TTM) Revenue $17.53m
EBIT (operating result TTM) EBIT $-35.21m
Free Cash Flow (TTM) Free Cash Flow $-22.72m
Cash position $10.31m
EPS (TTM) EPS $-30.82
P/E forward negative
P/S forward 0.73
EV/Sales forward 6.79
Short interest 1.20%
Show more

Is Codex DNA Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Codex DNA Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a Codex DNA Inc forecast:

2x Buy
67%
1x Hold
33%

Analyst Opinions

3 Analysts have issued a Codex DNA Inc forecast:

Buy
67%
Hold
33%

Financial data from Codex DNA Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
18 18
44% 44%
100%
- Direct Costs 12 12
14% 14%
71%
5.16 5.16
69% 69%
29%
- Selling and Administrative Expenses 24 24
25% 25%
140%
- Research and Development Expense 12 12
36% 36%
68%
-31 -31
9% 9%
-178%
- Depreciation and Amortization 3.96 3.96
8% 8%
23%
EBIT (Operating Income) EBIT -35 -35
8% 8%
-201%
Net Profit -50 -50
24% 24%
-283%

In millions USD.

Don't miss a Thing! We will send you all news about Codex DNA Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Codex DNA Inc Stock News

Neutral
Seeking Alpha
almost 2 years ago
Telesis Bio, Inc. (NASDAQ:DNAY ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Todd Nelson - CEO Brent Hunter - VP, Finance Conference Call Participants Brandon Couillard - Jefferies Operator Welcome to the Q3 2022 Telesis Bio Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Neutral
GlobeNewsWire
almost 2 years ago
SAN DIEGO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Telesis Bio (Nasdaq: DNAY), a leader in automated multi-omic and synthetic biology solutions, today announced that it will release its third quarter 2022 financial results on Tuesday, November 8, 2022, after the market closes. In conjunction with the release, management will host a conference call the same day at 1:30 p.m. Pacific Time / 4:30 p.m. Ea...
Neutral
GlobeNewsWire
almost 2 years ago
Novel name reflects expansion of capabilities and solutions Novel name reflects expansion of capabilities and solutions

Company Profile

Codex DNA, Inc. engages in research and development of genomic tools for biomedical and industrial applications. It offers BioXp 3200 system and Gibson assembly reagents. The company was founded by Daniel G. Gibson and J. Craig Venter on March 24, 2011 and is headquartered in San Diego, CA.

Head office United States
CEO Eric Esser
Employees 147
Founded 2011
Website telesisbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today